Biogen Inc.
Explore Biogen
Core profile pages, annual revenue records, and related research hubs for this company.
Leadership History
3 leaders · Full leadership timeline
Biogen was founded by scientists at the dawn of commercial biotechnology. Its modern identity was built around multiple sclerosis and later rare disease, but the company is now trying to prove that a broader neuroscience portfolio can support sustainable growth.
Biogen makes money through specialty drug sales, collaboration revenue, royalties, and profit-sharing arrangements. The company focuses on neurologists, rare-disease specialists, specialty pharmacies, payers, and partners in areas where clinical expertise and market access matter.
President and Chief Executive Officer
Viehbacher is leading Biogen's portfolio reset, cost discipline, business development, and focus on sustainable neuroscience growth.
Executive Vice President, Chief Legal Officer
Alexander has been a long-serving legal and governance leader during Biogen's evolution as a public biopharma company.
Executive Vice President and Chief Financial Officer
Kramer leads financial management and capital allocation during Biogen's transition beyond mature MS products.
Biogen faces mature MS erosion, competition in spinal muscular atrophy, complex Alzheimer's commercialization, payer scrutiny, high R&D risk, and the need to balance cost reductions with pipeline investment.
Christopher A. Viehbacher is President and Chief Executive Officer of Biogen.
Christopher A. Viehbacher's priority is sustainable growth, portfolio discipline, cost productivity, and rebuilding the pipeline beyond legacy MS products.
Biogen's executive team is focused on neuroscience commercialization, R&D prioritization, business development, and operational efficiency.
Biogen competes by concentrating on specialist neuroscience markets, lifecycle management, targeted business development, payer access, and scientific credibility in hard-to-treat diseases.
The leadership risk is that cost discipline and portfolio pruning could weaken long-term innovation if pipeline bets do not mature.